	US 11,672,805 B2
	Deuterated analogs of etifoxine, their derivatives and uses thereof
Olivier Dasse, Foothills Ranch, CA (US)
Assigned to GABA THERAPEUTICS INC., Newport Beach, CA (US)
Filed by GABA Therapeutics Inc., Newport Beach, CA (US)
Filed on Aug. 7, 2020, as Appl. No. 16/988,586.
Application 16/988,586 is a continuation of application No. 16/138,509, filed on Sep. 21, 2018, granted, now 10,736,901.
Application 16/138,509 is a continuation of application No. 15/557,748, granted, now 10,080,755, issued on Sep. 25, 2018, previously published as PCT/US2016/023231, filed on Mar. 18, 2016.
Claims priority of provisional application 62/135,979, filed on Mar. 20, 2015.
Prior Publication US 2020/0405726 A1, Dec. 31, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/535 (2006.01); A61P 25/00 (2006.01); A61K 31/536 (2006.01); A61K 31/015 (2006.01); A61K 31/03 (2006.01); C07B 59/00 (2006.01); C07D 265/18 (2006.01)

CPC A61K 31/535 (2013.01) [A61K 31/015 (2013.01); A61K 31/03 (2013.01); A61K 31/536 (2013.01); A61P 25/00 (2018.01); C07B 59/002 (2013.01); C07D 265/18 (2013.01); A61K 2300/00 (2013.01)]

17 Claims

1. A method of treating anxiety in a subject in need thereof comprising:

administering to said subject an effective amount of 6-chloro-N-(ethyl-d5)-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-amine or a pharmaceutically acceptable salt thereof.